Cited by Potent antibodies against immune invasive SARS-CoV-2 Omicron subvariants

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection DOI

Sebastian Havervall, Ulrika Marking,

Julia Svensson

et al.

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 387(14), P. 1333 - 1336

Published: Sept. 14, 2022

nated, 0 to 13 days, 14 27 1 2 months, 3 4 5 6 7 8 or ≥9 months).Among the patients who had received two doses of vaccine, waning effectiveness against hospitalization was evident as early months after vaccination during both periods when omicron sublineages were dominant.The vaccine 56.3% (95% confidence interval [CI], 51.6 60.5) BA.1-BA.2wave and 47.4% CI, 19.9 65.5) BA.4-BA.5 wave (Table 1).Although boosting with a third dose maintained severe disease caused by all four at decreased an 50.0%(95% 4.4 73.9) 46.8% 35.3 56.2) wave.Thus, either three BNT162b2 we found rapid current variant respect protection hospitalization.Our data indicate that maintains sublineages, although evidence durability indicates need for regular last vaccines incorporate variants concern maintain protection.

Language: Английский

Citations

197

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion DOI

Delphine Planas, Isabelle Staropoli, Vincent Michel

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: March 13, 2024

Abstract The unceasing circulation of SARS-CoV-2 leads to the continuous emergence novel viral sublineages. Here, we isolate and characterize XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16.1, EG.5.1.1, EG.5.1.3, XBF, BA.2.86.1 JN.1 variants, representing >80% circulating variants in January 2024. XBB subvariants carry few but recurrent mutations spike, whereas harbor >30 additional changes. These replicate IGROV-1 no longer Vero E6 are not markedly fusogenic. They potently infect nasal epithelial cells, with EG.5.1.3 exhibiting highest fitness. Antivirals remain active. Neutralizing antibody (NAb) responses from vaccinees BA.1/BA.2-infected individuals lower compared BA.1, without major differences between variants. An breakthrough infection enhances NAb against both BA.2.86 displays affinity ACE2 higher immune evasion properties BA.2.86.1. Thus, while distinct, evolutionary trajectory these combines increased fitness evasion.

Language: Английский

Citations

129

TMPRSS2 is a functional receptor for human coronavirus HKU1 DOI

Nell Saunders, I. Fernández, Cyril Planchais

et al.

Nature, Journal Year: 2023, Volume and Issue: 624(7990), P. 207 - 214

Published: Oct. 25, 2023

Language: Английский

Citations

SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells DOI

Nicolas Huot, Cyril Planchais,

Pierre Rosenbaum

et al.

Nature Immunology, Journal Year: 2023, Volume and Issue: 24(12), P. 2068 - 2079

Published: Nov. 2, 2023

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA generally becomes undetectable in upper airways after a few days or weeks postinfection. Here we used model of viral infection macaques to address whether SARS-CoV-2 persists the body and which mechanisms regulate its persistence. Replication-competent virus was detected bronchioalveolar lavage (BAL) macrophages beyond 6 months Viral propagation BAL occurred from cell inhibited by interferon-γ (IFN-γ). IFN-γ production strongest NKG2r+CD8+ T cells NKG2Alo natural killer (NK) further increased NK spike protein stimulation. However, impaired with persisting virus. Moreover, also enhanced expression major histocompatibility complex (MHC)-E on macrophages, possibly inhibiting cell-mediated killing. Macaques less mounted adaptive that escaped MHC-E-dependent inhibition. Our findings reveal an interplay between regulated persistence mediated IFN-γ.

Language: Английский

Citations

Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications DOI

Endeshaw Chekol Abebe, Tadesse Asmamaw Dejenie

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Jan. 19, 2023

Neutralizing antibodies (NAbs) are central players in the humoral immunity that defends body from SARS-CoV-2 infection by blocking viral entry into host cells and neutralizing their biological effects. Even though NAbs primarily work antigens, on some occasions, they may also combat virus escaping neutralization employing several effector mechanisms collaboration with immune like natural killer (NK) phagocytes. Besides prophylactic therapeutic roles, can be used for COVID-19 diagnosis, severity evaluation, prognosis assessment clinical practice. Furthermore, measurement of could have key implications determining individual or herd against SARS-CoV-2, vaccine effectiveness, duration protective response, as well aiding selection suitable individuals who donate convalescent plasma to treat infected people. Despite all these applications NAbs, using them settings present challenges. This review discusses functions, possible potential COVID-19. article highlights challenges solutions associated antibody-based prophylaxis, therapy, vaccination.

Language: Английский

Citations

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion DOI

Delphine Planas, Isabelle Staropoli, Vincent Michel

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Nov. 21, 2023

The unceasing circulation of SARS-CoV-2 leads to the continuous emergence novel viral sublineages. Here, we isolated and characterized XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16.1, EG.5.1.1, EG.5.1.3, XBF, BA.2.86.1 JN.1 variants, representing >80% circulating variants in January 2024. XBB subvariants carry few but recurrent mutations spike, whereas harbor >30 additional changes. These replicated IGROV-1 no longer Vero E6 were not markedly fusogenic. They potently infected nasal epithelial cells, with EG.5.1.3 exhibiting highest fitness. Antivirals remained active. Neutralizing antibody (NAb) responses from vaccinees BA.1/BA.2-infected individuals lower compared BA.1, without major differences between variants. An breakthrough infection enhanced NAb against both BA.2.86 displayed affinity ACE2 higher immune evasion properties BA.2.86.1. Thus, while distinct, evolutionary trajectory these combines increased fitness evasion.

Language: Английский

Citations

Structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus DOI

I. Fernández, Nell Saunders, S. Duquerroy

et al.

Cell, Journal Year: 2024, Volume and Issue: 187(16), P. 4246 - 4260.e16

Published: Aug. 1, 2024

Language: Английский

Citations

A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity DOI

Leire de Campos‐Mata, Benjamin Trinité, Andrea Modrego

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Feb. 5, 2024

Abstract Here we report the characterization of 17T2, a SARS-CoV-2 pan-neutralizing human monoclonal antibody isolated from COVID-19 convalescent individual infected during first pandemic wave. 17T2 is class 1 VH1-58/κ3-20 antibody, derived receptor binding domain (RBD)-specific IgA + memory B cell, with broad neutralizing activity against former and new variants, including XBB.1.16 BA.2.86 Omicron subvariants. Consistently, demonstrates in vivo prophylactic therapeutic BA.1.1 infection K18-hACE2 mice. Cryo-electron microscopy reconstruction shows that binds BA.1 spike RBD “up” position blocks motif, as other structurally similar antibodies do, S2E12. Yet, unlike S2E12, retains its all variants tested, probably due to larger contact area. These results highlight impact small structural changes on performance identify potential candidate for future clinical interventions.

Language: Английский

Citations

Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2 DOI

Klara Lenart, Rodrigo Arcoverde Cerveira,

Fredrika Hellgren

et al.

npj Vaccines, Journal Year: 2024, Volume and Issue: 9(1)

Published: Jan. 20, 2024

Abstract The immune responses to Novavax’s licensed NVX-CoV2373 nanoparticle Spike protein vaccine against SARS-CoV-2 remain incompletely understood. Here, we show in rhesus macaques that immunization with Matrix-M TM adjuvanted vaccines predominantly elicits events local tissues little spillover the periphery. A third dose of an updated based on Gamma (P.1) variant 7 months after two immunizations resulted significant enhancement anti-spike antibody titers and breadth including neutralization forward drift Omicron variants. expanded Spike-specific memory B cell pool, induced somatic hypermutation, increased serum avidity, indicating considerable affinity maturation. Seven immunization, vaccinated animals controlled infection by either WA-1 or P.1 strain, mediated rapid anamnestic T lungs. In conclusion, a adjuvanted, low-dose recombinant significantly improved quality responses, enhanced breadth, provided durable protection challenge.

Language: Английский

Citations

Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies DOI

Delphine Planas, Isabelle Staropoli, Cyril Planchais

et al.

Pathogens and Immunity, Journal Year: 2024, Volume and Issue: 10(1), P. 1 - 11

Published: Sept. 30, 2024

First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence resistant Omicron variants. In 2024, 2 novel mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were approved by health authorities, but their activity against contemporary JN.1 sublineages is poorly characterized.

Language: Английский

Citations